Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical
View original at finance.yahoo.comZacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical For Immediate Release Chicago, IL – December 30, 2025 – Today, Zacks Equity Research discusses Veracyte VCYT, IDEXX Laboratories IDXX and Intuitive Surgical ISRG…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Intuitive Surgical's 2025 EPS consensus estimate is $8.65, representing 17.9% growth year-over-year
80% confidenceThe Medical Instruments industry's five-year P/E range has been as high as 40.76X, as low as 25.73X, with a median of 32.28X
80% confidenceThe Zacks Medical Instruments industry is trading at a forward 12-month P/E of 30.36X, compared with the broader industry's 21.29X and the S&P 500's 23.42X
80% confidenceOverall MedTech M&A activity remained below historical norms, with only 46 announced deals through November 30, 2025
80% confidenceIntuitive Surgical's 2025 sales consensus estimate is $9.92 billion, representing 18.7% growth from 2024
80% confidenceVeracyte's 2025 EPS consensus estimate is $1.65, representing 38.7% growth from 2024
80% confidenceIDEXX Laboratories' 2025 EPS consensus estimate is $12.93, representing 21.2% growth
80% confidenceThe Zacks Medical Instruments industry carries a Zacks Industry Rank #161, placing it in the bottom 33% of 243 Zacks industries
80% confidenceGlobal headline inflation is expected to decline to 4.2% in 2025 and to 3.7% in 2026
80% confidenceIDEXX Laboratories holds a Zacks Rank #2 (Buy)
80% confidenceThe top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1
80% confidenceGlobal generative AI in the healthcare market is valued at $2.64 billion in 2025 and is expected to witness a CAGR of 35.2% through 2034
80% confidenceGlobal growth is expected to remain at 3.2% in 2025 and 3.1% in 2026, below the pre-pandemic average of 3.7%
80% confidenceZacks top stock-picking strategies have averaged gains of +48.4%, +50.2%, and +56.7% per year since 2000, versus the S&P's +7.7% average annual gain
80% confidenceThe application of AI in the diagnostics space is growing enormously, with the market expected to witness a CAGR of 20.4% by 2034
80% confidenceVeracyte's 2025 sales consensus estimate is $508.6 million, representing 14.1% growth from 2024
80% confidenceIDEXX Laboratories' 2025 sales consensus estimate is $4.28 billion, representing 9.9% growth
80% confidenceMedTech deal value surged to $92.8 billion in 2025, the highest level in more than a decade, driven by three mega-deals
80% confidenceIntuitive Surgical holds a Zacks Rank #2 (Buy)
80% confidenceVeracyte holds a Zacks Rank #1 (Strong Buy)
80% confidenceGlobal AI in the healthcare market is projected to witness a CAGR of 44% from 2025 to 2032
80% confidence
